AKIE-CRRTNCT05036616
Separation Versus Integrated Approach in Combining ECMO With CRRT
A study testing Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy in people with AKI, run by Chulalongkorn University at 1 site in Thailand.
Trial summary
This study aimed to compare circuit lifespan of CRRT between Integration and Separation techniques during ECMO support. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- AKI
- What is being tested?
- Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 80 participants
- Where
- 1 siteThailand
- Study dates
- 1 Apr 2021to 31 Aug 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- Pregnancy
- Heparin contraindication
- Chronic kidney disease with CRRT
- AKI with Glomerulonephritis, Interstitial nephritis, Vassculitis or Urinary tract obstruction
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Separation Versus Integrated Approach in Combining ECMO With CRRT, a Randomized Controlled Trial
This study aimed to compare circuit lifespan of CRRT between Integration and Separation techniques during ECMO support.
- Conditions
- AKI
- Being tested
- Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy
- Keywords
- CRRT, ECMO, integration, circuit, combination
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Combination of extracorporeal membrane oxygenation and continuous renal replacement therapyDevice
Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy
| Study group | Role | What they receive |
|---|---|---|
| Separation technique | Experimental | Not described Receives: Device: Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy |
| Integration technique | Experimental | Not described Receives: Device: Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
CRRT Circuit lifespan
The time until a CVVHDF malfunction was identified
Measured: 72 hours, extended maximum to 120 hours
Secondary outcomes (3)
Serious Adverse Events
Bleeding at exit site, systemic bleeding, need for blood transfusion, air embolism, positive-blood culture infection, hemolysis
Measured: [Time Frame: 72 hours, extended maximum to 120 hours of filter lifespan]
28-day mortality
28-day mortality, status yes or no
Measured: 28-day after randomization
Pressure at various points of CRRT circuit
Pressure point at CRRT circuit; access pressure, return pressure, filter pressure, Pressure drop, and Transmembrane pressure
Measured: [Time Frame: 72 hours, extended maximum to 120 hours of filter lifespan]
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Sep 2021
- Study start1 Apr 2021
- Primary completion10 Mar 2025
- Study completion31 Aug 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for AKIStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 80 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chulalongkorn University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nattachai Srisawat ,M.D., Chulalongkorn University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05036616
- Sponsor's protocol ID
- IRB.151/64
- Acronym
- E-CRRT
- Status last verified
- Dec 2025
- First submitted
- 26 Aug 2021
- Last updated
- 19 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Thy M, Augustin P, Tran-Dinh A, Montravers P, de Tymowski C. Renal Replacement Therapy for Patients Requiring Extracorporeal Membrane Oxygenation: A Multicenter International Survey. Blood Purif. 2022;51(11):899-906. doi: 10.1159/000522398. Epub 2022 Apr 7.
PubMed 35390796de Tymowski C, Desmard M, Lortat-Jacob B, Pellenc Q, Alkhoder S, Alouache A, Fritz B, Montravers P, Augustin P. Impact of connecting continuous renal replacement therapy to the extracorporeal membrane oxygenation circuit. Anaesth Crit Care Pain Med. 2018 Dec;37(6):557-564. doi: 10.1016/j.accpm.2018.02.024. Epub 2018 Mar 20.
PubMed 29572101Tangjitaree P, Thanapongsatorn P, Sinjira T, Surinrat E, Suttiruk P, Srisawat N. The comparison of circuit lifespan between integration and separation approach in extracorporeal membrane oxygenation patients requiring continuous renal replacement therapy support: a randomized controlled trial (E-CRRT Trial). Intensive Care Med. 2026 Mar;52(3):434-444. doi: 10.1007/s00134-026-08302-y. Epub 2026 Feb 5.
PubMed 41642325
Study at a glance
From the registry record, last updated by the sponsor on 19 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Separation Versus Integrated Approach in Combining ECMO With CRRT, a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT05036616
- Acronym / sponsor ID
- E-CRRT / IRB.151/64
- Conditions
- AKI
- Keywords
- CRRT, ECMO, integration, circuit, combination
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 80 participants (actual)
- Lead sponsor
- Chulalongkorn UniversityUniversity, hospital or other
- Study start
- 1 Apr 2021 (actual)
- Primary completion
- 10 Mar 2025 (actual)
- Study completion
- 31 Aug 2025 (actual)
- First posted
- 5 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to compare circuit lifespan of CRRT between Integration and Separation techniques during ECMO support.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Separation technique | Experimental | Device: Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy |
| Integration technique | Experimental | Device: Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (4 listed)
- Pregnancy
- Heparin contraindication
- Chronic kidney disease with CRRT
- AKI with Glomerulonephritis, Interstitial nephritis, Vassculitis or Urinary tract obstruction
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Combination of extracorporeal membrane oxygenation and continuous renal replacement therapyCombination of extracorporeal membrane oxygenation and continuous renal replacement therapy | Device | Integration technique, Separation technique |
Primary outcome
CRRT Circuit lifespan
Time frame: 72 hours, extended maximum to 120 hours
The time until a CVVHDF malfunction was identified
3 secondary outcomes
Serious Adverse Events
Time frame: [Time Frame: 72 hours, extended maximum to 120 hours of filter lifespan]
28-day mortality
Time frame: 28-day after randomization
Pressure at various points of CRRT circuit
Time frame: [Time Frame: 72 hours, extended maximum to 120 hours of filter lifespan]
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Dec 2025.
- Background: PubMed 35390796Thy M, Augustin P, Tran-Dinh A, Montravers P, de Tymowski C. Renal Replacement Therapy for Patients Requiring Extracorporeal Membrane Oxygenation: A Multicenter International Survey. Blood Purif. 2022;51(11):899-906. doi: 10.1159/000522398. Epub 2022 Apr 7.
- Background: PubMed 29572101de Tymowski C, Desmard M, Lortat-Jacob B, Pellenc Q, Alkhoder S, Alouache A, Fritz B, Montravers P, Augustin P. Impact of connecting continuous renal replacement therapy to the extracorporeal membrane oxygenation circuit. Anaesth Crit Care Pain Med. 2018 Dec;37(6):557-564. doi: 10.1016/j.accpm.2018.02.024. Epub 2018 Mar 20.
- Derived from this study: PubMed 41642325Tangjitaree P, Thanapongsatorn P, Sinjira T, Surinrat E, Suttiruk P, Srisawat N. The comparison of circuit lifespan between integration and separation approach in extracorporeal membrane oxygenation patients requiring continuous renal replacement therapy support: a randomized controlled trial (E-CRRT Trial). Intensive Care Med. 2026 Mar;52(3):434-444. doi: 10.1007/s00134-026-08302-y. Epub 2026 Feb 5.
Related trials for AKI
Recruiting
NIRS Monitoring in the NICU and AKI
Acute Kidney Injury (AKI), Postnatal AKI
Not yet recruitingPhase 2
Amino Acid Therapy Evaluating the Incidence of New-Onset AKI
Acute Kidney Injury
Recruiting
COordiNated CommuNication, Education, and Care Transitions After Acute Kidney Injury (CONNECT-AKI)
Acute Kidney Injury, Acute Kidney Injury (AKI)
RecruitingPhase 4
The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)
Infection, Acute Kidney Injury
RecruitingPhase 2
Prevent Cardiac Surgery Associated AKI Trial
Renal Failure, Coronary Artery Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Combination of extracorporeal membrane oxygenation and continuous renal replacement therapy in people with AKI, run by Chulalongkorn University at 1 site in Thailand.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Thailand. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
CRRT Circuit lifespan (time frame: 72 hours, extended maximum to 120 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05036616, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2025.